骨碎补总黄酮通过PDGF-BB/PDGFR-β而非HIF-1α/VEGF轴促进牵张成骨中H型血管形成增强血管-成骨耦联
本研究在大鼠牵张成骨(DO)与骨折模型中观察骨碎补总黄酮(TFRD)对H型血管及血管-成骨耦联的影响。结果显示DO组H型血管多于骨折组,TFRD增加H型血管丰度并改善成骨;体外TFRD通过PDGF-BB/PDGFR-β而非HIF-1α/VEGF轴促进内皮祖细胞血管生成及BMSCs成骨。
要点
- DO模型中存在H型血管,TFRD可增加其丰度并改善血管-成骨耦联。
- TFRD促血管生成依赖PDGF-BB/PDGFR-β轴,阻断PDGF-BB可抑制该效应。
- HIF-1α抑制剂不影响TFRD激活的AKT/ERK1/2及管腔形成。
核心结论
- TFRD通过PDGF-BB/PDGFR-β而非HIF-1α/VEGF轴促进H型血管形成,增强DO中血管-成骨耦联。
研究设计与样本
- 建立大鼠DO与骨折(FR)模型并分TFRD组与对照组,行影像学与组织学分析。
- 免疫荧光CD31与Emcn染色检测H型血管。
- 体外用Matrigel管腔形成、ALP及茜素红染色检测EPCs与BMSCs的血管生成或成骨。
- ELISA、qPCR或western blot检测HIF-1α、VEGF、PDGF-BB、RUNX2、OSX表达。
主要发现
- DO组H型血管多于FR组,TFRD明显增加H型血管丰度。
- H型血管丰度较高的组显示更好的血管生成与成骨结果。
- 体外TFRD显著促进应激条件下EPCs血管生成活性,阻断PDGF-BB则显著抑制。
- TFRD上调p-AKT与p-ERK1/2,抗PDGF-BB抗体阻断该上调。
- HIF-1α抑制剂不影响TFRD激活的AKT/ERK1/2及管腔形成。
临床怎么用
- DO过程中可关注H型血管作为血管-成骨耦联的评估指标。
- TFRD或可经PDGF-BB/PDGFR-β通路促进DO中H型血管形成与成骨。
- 联合PDGF-BB通路阻断时需注意其对TFRD促血管生成与成骨效应的潜在抑制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Total flavonoids of Rhizoma Drynariae (TFRD), extracted from the kidney-tonifying traditional Chinese medicine Rhizoma Rrynariae, has been proved to be effective in treating osteoporosis, bone fractures and defects. However, pharmacological effects of TFRD on type H vessels, angiogenic-osteogenic coupling in distraction osteogenesis (DO) and the mechanism remain unclear. This study aims at investigating whether type H vessels exist in the DO model, effects of TFRD on angiogenic-osteogenic coupling and further elucidating the underlying mechanism. Methods: Rats models of DO and bone fracture (FR) were established, and then were separately divided into TFRD and control subgroups. Imageological and histological analyses were performed to assess bone and vessel formation. Immunofluorescent staining of CD31 and endomucin (Emcn) was conducted to determine type H vessel formation. Matrigel tube formation, ALP and Alizarin Red S staining assays were performed to test the effects of TFRD on angiogenesis or osteogenesis of endothelial precursor cells (EPCs) or bone marrow-derived mesenchymal stem cells (BMSCs). Additionally, expression levels of HIF-1α, VEGF, PDGF-BB, RUNX2 and OSX were determined by ELISA, qPCR or western blot, respectively. Results: The in vivo results indicated more formed type H vessels in DO groups than in FR groups and TFRD obviously increased the abundance of type H vessels. Moreover, groups with higher abundance of type H vessels showed better angiogenesis and osteogenesis outcomes. Further in vitro experiments showed that TFRD significantly promoted while blocking PDGF-BB remarkably suppressed the angiogenic activity of EPCs under stress conditions. The levels of p-AKT and p-ERK1/2, downstream mediators of the PDGF-BB pathway, were up-regulated by TFRD but blocked by function blocking anti-PDGF-BB antibody. In contrast, the activated AKT and ERK1/2 and corresponding tube formation were not affected by the HIF-1α inhibitor. Besides, blocking PDGF-BB inhibited the osteogenic differentiation of the stretched BMSCs, but TFRD enhanced the osteogenic activity of BMSCs and ameliorated the inhibition, with more calcium nodes, higher ALP activity and mRNA and protein levels of RUNX2 and OSX. Conclusion: Type H vessels exist in the DO model and TFRD enhances angiogenic-osteogenic coupling during DO by promoting type H vessel formation via PDGF-BB/PDGFR-β instead of HIF-1α/VEGF axis.
引用
- Shen Z, Chen Z, Li Z, et al. Total Flavonoids of Rhizoma Drynariae Enhances Angiogenic-Osteogenic Coupling During Distraction Osteogenesis by Promoting Type H Vessel Formation Through PDGF-BB/PDGFR-β Instead of HIF-1α/ VEGF Axis. Front Pharmacol. 2020. PMID: 33328980. doi:10.3389/fphar.2020.503524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。